What is the Capizzi induction regimen (continuous‑infusion cytarabine 20 mg/m² per hour for 10 days plus idarubicin 12 mg/m² IV on days 1‑3) for older or medically frail adults with acute myeloid leukaemia, and what supportive care and alternative low‑intensity options should be considered?

Capizzi Protocol for Older/Frail Adults with AML

What is the Capizzi Regimen?

The term "Capizzi protocol" does not appear in current NCCN guidelines or standard AML literature for older adults. You may be confusing terminology—there is no established "Capizzi induction regimen" using continuous-infusion cytarabine 20 mg/m² per hour for 10 days plus idarubicin 12 mg/m² IV on days 1-3 for older or medically frail adults with AML. 1

The evidence describes several distinct regimens that use similar components but in different dosing schedules:

Low-Dose Cytarabine Regimens (Not Capizzi)

• Low-dose cytarabine is administered as 20 mg twice daily (not per hour) for 10 consecutive days subcutaneously or IV, achieving only 18% CR rates with 26% induction mortality when used alone 1
• This can be combined with clofarabine (20 mg/m² daily for 5 days), achieving 58% CR rates and 12.7 months median OS in patients ≥60 years 1
• Glasdegib plus low-dose cytarabine (20 mg twice daily for 10 days every 28 days) is FDA-approved for patients ≥75 years or those with comorbidities, achieving 17% CR rates and 8.8 months median OS 1

Standard Intensive Regimens with Idarubicin

• Standard "7+3" induction uses cytarabine 100-200 mg/m² continuous infusion for 7 days (not 10) plus idarubicin 12 mg/m² IV on days 1-3, achieving 40-50% CR rates in older adults with NK-AML 1
• This regimen is reserved for fit older adults (ECOG 0-2, minimal comorbidity, favorable/intermediate cytogenetics) 1

Current Standard Treatment Recommendations

For Medically Frail/Unfit Older Adults (≥75 years or significant comorbidities)

Venetoclax plus hypomethylating agents (azacitidine or decitabine) is the current FDA-approved standard of care, achieving 67% CR/CRi rates with 17.5 months median OS and 11.3 months median duration of remission 1, 2, 3:

• Venetoclax 400 mg orally daily plus azacitidine 75 mg/m² subcutaneously or IV for 7 days every 28 days 1, 3
• Superior outcomes compared to low-dose cytarabine alone (67% vs 18% CR rates) 1
• Febrile neutropenia occurs in 30-61% of patients; infections occur in 84% 3

Alternative Low-Intensity Options (if venetoclax unavailable/contraindicated)

• HMA monotherapy (azacitidine or decitabine alone) 1, 3
• Glasdegib 100 mg daily plus low-dose cytarabine (20 mg twice daily for 10 days every 28 days) 1
• Low-dose cytarabine plus clofarabine (20 mg/m² daily for 5 days) 1

For Fit Older Adults (60-75 years, ECOG 0-2, minimal comorbidity, favorable/intermediate cytogenetics)

Standard intensive "7+3" induction remains appropriate 1:

• Cytarabine 100-200 mg/m² continuous infusion for 7 days plus idarubicin 12 mg/m² IV on days 1-3 1
• Achieves 40-50% CR rates but carries 10% induction mortality risk 1
• Followed by multiple cycles of consolidation with intermediate-dose cytarabine 4

Critical Supportive Care Requirements

Infection Prophylaxis

• Prophylactic antibiotics, antifungals, and antivirals during neutropenic periods 4
• Febrile neutropenia management protocols 4, 3

Transfusion Support

• Red blood cell and platelet transfusions as needed during profound myelosuppression 4, 3

Tumor Lysis Syndrome Prevention

• Hydration, allopurinol or rasburicase, electrolyte monitoring 3

Monitoring Requirements

• Daily CBC and twice-weekly chemistry panels during induction 4
• Bone marrow assessment around day 14-21 to evaluate response 1, 4
• Cardiac monitoring if anthracyclines used (baseline and periodic echocardiograms) 4

Common Pitfalls to Avoid

• Do not use age alone to exclude patients from intensive therapy—functional status, comorbidities, and cytogenetics matter more than chronologic age 1, 4
• Do not discontinue HMA-based therapy prematurely—responses may not be evident before 3-4 cycles as HMAs require active DNA replication 1, 3
• Do not use best supportive care alone when low-intensity therapy is feasible—79.7% of untreated elderly AML patients die within 60 days 2, 3
• Do not underestimate early mortality risk—even with low-intensity approaches, induction death occurs in 4-26% of patients depending on regimen 1, 2
• Recognize that cytogenetics and molecular markers critically modify outcomes—TP53-mutated AML achieves only 47% CR/CRi rates even with venetoclax-HMA, while NPM1-mutated AML achieves 89% 1, 2